產(chǎn)品列表

—— PROUCTS LIST

新聞動態(tài)News 當(dāng)前位置：首頁 > 新聞動態(tài) > 金秋獻(xiàn)禮，共慶雙節(jié)｜一份實(shí)用的血液腫瘤免疫表型參考圖表，請收好！

金秋獻(xiàn)禮，共慶雙節(jié)｜一份實(shí)用的血液腫瘤免疫表型參考圖表，請收好！

點(diǎn)擊次數(shù)：166 更新時(shí)間：2025-09-26

免疫表型（Immunophenotype）是指細(xì)胞表面、細(xì)胞內(nèi)或分泌的蛋白質(zhì)（主要是抗原）的表達(dá)模式。不同的細(xì)胞系列（如淋巴細(xì)胞、髓系細(xì)胞）和細(xì)胞發(fā)育的不同階段，都會表達(dá)獨(dú)特的CD抗原組合。

免疫表型檢測，在臨床實(shí)踐中通常通過流式細(xì)胞術(shù)（Flow Cytometry）或免疫組化（Immunohistochemistry）來實(shí)現(xiàn)，是現(xiàn)代血液腫瘤診療中不可或缺的核心技術(shù)之一。它被譽(yù)為血液病醫(yī)生的“火眼金睛"，其作用貫穿于血液腫瘤的診斷、分型、預(yù)后判斷和治療監(jiān)測的全過程。

上周我們更新了一篇非淋系的WHO-HAEM5（第5版造血與淋巴組織腫瘤分類）的疾病名稱中英文對照。

第5版WHO造血淋巴腫瘤疾病名稱中英文對照—非淋系篇

這周我們來看一下，根據(jù)WHO-HAEM5（第5版造血與淋巴組織腫瘤分類），而制作的免疫表型的表達(dá)圖譜，供血液從業(yè)者日常使用參考。

免疫表型的表達(dá)圖譜

（點(diǎn)擊圖片查看高清大圖）

說明

（上下滑動閱覽）

Waldenstr?m macroglobulinema (ICD-O code=9761/3) is found in a significant subset of patients with lymphoplasmacytic lymphoma with BM involvement and an IgM monoclonal gammopathy of any concentration.
In Heavy Chain Diseases, intracellular Ig heavy chains are not always IgMs.
Typically IgM+, and less often IgA+ or IgG+.
IgD is positive in a minority of the cases.
IgM+/-, IgD, IgG or rarely IgA.
More frequently with Lambda than Kappa restriction.
The membrane expression of CD3 may be weak.
25% of patients coexpress CD8 with CD4, a feature almost unique to T-PLL. 15% are CD4-neg, CD8-pos.
Expression of CD94/NKG2 and KIR families of receptors can be detected in 50% or more of cases.
Uncommon variants include CD4 TCRα/β-pos cases and TCRγ/δ-pos cases. Approximately 60% of the latter express CD8, the remainder are CD4/CD8-neg.
Abnormal uniform expression of CD8 can be seen.
KIR-pos cases preferentially express activating receptor isoforms.
If TCRα/β-positive, expect dierent immunophenotype for the rest of the markers.
A CD4-pos/CD8-neg phenotype predominates in nodal cases. CD4/CD8 double positivity or double negativity is at times seen.
CD13 with heterogeneous expression.
Co-expression of CD15 and strong CD64 is characteristic of monocytic dierentiation.
CD25 is highly associated with t(9;22) B-ALL, at least in adults.
NG2 is characteristically expressed and is relatively, though not absolutely, specific.
The cortical T stage shows a double positive (CD4-pos/CD8-pos) phenotype. The medullary T stage expresses only either CD4 or CD8.
IgM+/IgD+ as for B-CLL/SLL
When t(14;18) IGH/BCL2 is present, bcl2 expression is bright
>90% of cases also express Sox-11 by IHC
MYC protein is strongly expressed due to translocation of the MYC gene to the IGH, IGK, or IGL genes.
All immunophenotypes for T-ALL/T-LBL are based on IHC and NOT flow cytometry
In AML with inv(16), CD14 and CD64 are mainly expressed by the monocytic component of this AML with myelomonocytic dierentiation, and CD16 is mainly expressed by the granulocytic component
In AML with t(15;17), CD2, CD34, and CD123 are most commonly expressed by the microgranular variant
In AML with NPM1 mutation, the immunophenotype diers between cases with prominent monocytic dierentiation and cases with prominent myeloblastic morphology (the latter often has cuplike nuclear invagination if a concurrent FLT3-ITD mutation is present)
AML with RAM phenotype, a subset of megakaryoblastic AML, expresses high-level CD56 without CD7

掃碼登記即可下載資料

參考文獻(xiàn)（上下滑動閱覽）

1. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024.

2. Jae ES, Harris NL, Stein H, et al. Dendritic cell neoplasms: A review of the current classification. Am J Surg Pathol.

2022;46(1):100-112.

3. Feng J, Qiu Y, Zhang Y, et al. A review of the current concepts in the diagnosis and classification of dendritic cell tumors. J Clin Pathol. 2023;76(2):109-118.

4. Zhang L-F, Zhang Y, Shui R-H, et al. MNDA expression and its value in dierential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases. Diagn Pathol. 2024;19:60.

5. Choi JY, Lee JH, Yang WI. Reactive lymphoid hyperplasia in the lymph nodes of patients with lymphoma. Pathol Res Pract. 2021;217:153296.

6. Fujimoto M, Kikuchi M. Kikuchi's disease: the history and the current understanding of the disease. Ann Hematol.

2019;98(3):553-560.

7. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-551.

8. Wang Q, Liu H, Liu Q, et al. The clinical features of unicentric and multicentric Castleman disease: a single-center experience. Hematol Oncol. 2021;39(3):314-321.

9. Polizzotto MN, Uldrick TS, Wang V, et al. Kaposi sarcoma–associated herpesvirus (human herpesvirus 8) and the etiology of multicentric Castleman disease. Blood. 2019;133(11):1186-1197.

10. Geyer JT, Medeiros LJ, et al. Indolent T-lymphoblastic proliferation: A diagnostic dilemma. Mod Pathol. 2015;28(4):527-535.

11. Ponniah R, Chua I, et al. The challenges of diagnosing autoimmune lymphoproliferative syndrome. J Clin Pathol. 2018;71(7):651-658.

12. Krenacs T, et al. Rosai-Dorfman disease: A comprehensive review. Leuk Lymphoma. 2020;61(7):1534-1542.